A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Trial Profile

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs BGB 3111 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors BeiGene
  • Most Recent Events

    • 14 Jun 2017 According to a BeiGene media release, as of 31 March 2017, 69 patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (18 TN, 51 R/R) were enrolled in the study.
    • 14 Jun 2017 According to a BeiGene media release, clinical data from this study was presented at the 14th International Conference on Malignant Lymphoma (14-ICML) 2017.
    • 14 Jun 2017 According to a BeiGene media release, results published in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top